Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 42.54 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 47.78 | Oscillator | Neutral |
| Williams %R (14) | -56.67 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.15 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 19.32 (+DI 18.1 / -DI 26.5) | Trend | Neutral |
Current price $3.75
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 |
| EMA 20 | 3.91 | MA | Strong Sell |
| SMA 20 | 3.93 | MA | Strong Sell |
| EMA 50 | 4.27 | MA | Strong Sell |
| SMA 50 | 4.34 | MA | Strong Sell |
| SMA 200 | 5.27 | MA | Strong Sell |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Sep 30, 26 | JP Morgan | maintain | Overweight | Overweight |
| Sep 1, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 13, 26 | Citizens | upgrade | Market Underperform | Market Perform |
| Jul 15, 26 | Needham | maintain | Buy | Buy |
| Mar 20, 26 | Chardan Capital | maintain | Buy | Buy |
| Nov 19, 25 | Wells Fargo | maintain | Overweight | Overweight |
| Aug 15, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 14, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 25, 2026 | 2026-09-25 16:15:13 | View |
| 4 | Aug 12, 2026 | 2026-08-12 18:10:26 | View |
| 3 | Aug 12, 2026 | 2026-08-12 18:08:50 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:00:38 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 06:30:26 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 16:35:51 | View |
| SC 13G | Aug 7, 2026 | 2026-08-07 08:40:55 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 08:17:10 | View |
| 8-K | Jul 30, 2026 | 2026-07-30 16:25:02 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:24 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, supported by $209.2M in liquidity and a $200M Oxford Finance facility, but future financing remains a risk. The ARCHER II trial pivots to functional vision endpoints, with key readouts expected in Q4 2026 and potential market expansion if vision preservation is confirmed.
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los Angeles, California.
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.24 | -0.28 | Miss -17.2% | — |
| May 7, 2026 | -0.30 | -0.23 | Beat 23.3% | — |
| Mar 30, 2026 | -0.32 | -0.28 | Beat 12.5% | — |
| Nov 10, 2025 | -0.34 | -0.37 | Miss -8.8% | — |
| Aug 14, 2025 | -0.36 | -0.34 | Beat 5.6% | — |
| May 12, 2025 | -0.30 | -0.37 | Miss -23.3% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 24, 26 | Love Douglas | director, officer: PRESIDENT AND CEO | P-Purchase | 26,065 @ $3.83 | $99.83K |
| Aug 10, 26 | Blumenkranz Mark S. | director | A-Award | 175,000 @ $5.39 | $943.3K |
| Aug 10, 26 | Blumenkranz Mark S. | 0 | — | ||
| Jun 11, 26 | Waddill William D. | director | A-Award | 65,000 @ $4.70 | $305.5K |
| Jun 11, 26 | Satter Muneer A | director | A-Award | 65,000 @ $4.70 | $305.5K |
| Jun 11, 26 | Jones William A Jr | director | A-Award | 65,000 @ $4.70 | $305.5K |
| Jun 11, 26 | Cockroft Bettina M. | director | A-Award | 65,000 @ $4.70 | $305.5K |
| Jun 11, 26 | Choi Jung | director | A-Award | 65,000 @ $4.70 | $305.5K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANNX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.2x | -3.4x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.6x | EPS est. -1.05 | In line |
| Price / Book | 4.1x | 2.1x | Elevated |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -2.2x | -2.7x | Discount |
| Return on equity | -106.2% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.13 | 0.13 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -1.51 | Distress |
Discounted cash flow model